Revvity Debuts Inaugural ESG Report

Revvity, Inc. (NYSE: RVTY) today unveils its inaugural 2023 Environmental, Social and Governance (ESG) Report. An in-depth overview of the Company’s ESG strategy, initiatives and performance, the report showcases the Company’s deepening commitment to driving more sustainable solutions, along with a culture of transparency, empowerment and inclusivity.

“Revvity’s ESG program and goals boldly represent what we’re all about – ensuring that every day we are working to be better by not only helping advance science, but also doing so in a way that improves lives and the environment,” said Prahlad Singh, president and chief executive officer at Revvity. “With Revvity still in its infancy, it’s important we establish ambitious, yet realistic, ESG goals that will guide our progress and ensure accountability as we look to drive a positive impact on the world.”

Key goals highlighted in the report include:

  • Achieving a 50% reduction of the Company’s Scope 1 and 2 greenhouse gas emissions by 2033
  • Reaching net carbon neutrality by 2040
  • Achieving 40% non-hazardous waste landfill diversion by 2027
  • Maintaining greater than 40% female representation in leadership positions
  • Achieving greater than 75% employee satisfaction
  • Further evaluating and implementing gender pay equality commitments over the next 12 months

To learn more about Revvity’s ESG commitments and progress visit

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our NewsroomLinkedInXYouTubeFacebook and Instagram.

Investor Relations:
Steve Willoughby
[email protected]

Media Relations:
Chet Murray
[email protected]

< | >